Emmanuel Chiebuka Okoye

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial

Alexander Stratigos, Aleksandar Sekulić, Ketty Peris et al. · The Lancet Oncology · 2021 · 266 citations · Full text

Medicine, Hedgehog Inhibitor Therapy, Dermatology +5

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

Danny Rischin, Michael R. Migden, Annette M. Lim et al. · Journal for ImmunoTherapy of Cancer · 2020 · 169 citations · Full text

Depression, functional disability and quality of life among Nigerian older adults: Prevalences and relationships

Christopher Olusanjo Akosile, Ukamaka Gloria Mgbeojedo, Fatai Adesina Maruf et al. · Archives of Gerontology and Geriatrics · 2017 · 116 citations

Functional Disability, Quality Of Life, Life Satisfaction +11

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

Danny Rischin, Nikhil I. Khushalani, Chrysalyne D. Schmults et al. · Journal for ImmunoTherapy of Cancer · 2021 · 101 citations · Full text

Cancer Management, Median Time, Dermatology +16

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Mustafa Özgüroğlu, Ahmet Sezer, Mahmut Gümüş et al. · The Lancet Oncology · 2023 · 82 citations

First-line Cemiplimab Monotherapy, Empower-lung 1, Medicine +10